Fate Therapeutics (FATE) Competitors $1.07 -0.03 (-2.73%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.06 -0.01 (-0.47%) As of 08/1/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. ZVRA, TYRA, KROS, TRML, TSHA, ARVN, RZLT, TBPH, PRME, and SAGEShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Zevra Therapeutics (ZVRA), Tyra Biosciences (TYRA), Keros Therapeutics (KROS), Tourmaline Bio (TRML), Taysha Gene Therapies (TSHA), Arvinas (ARVN), Rezolute (RZLT), Theravance Biopharma (TBPH), Prime Medicine (PRME), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Its Competitors Zevra Therapeutics Tyra Biosciences Keros Therapeutics Tourmaline Bio Taysha Gene Therapies Arvinas Rezolute Theravance Biopharma Prime Medicine Sage Therapeutics Fate Therapeutics (NASDAQ:FATE) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership. Do analysts prefer FATE or ZVRA? Fate Therapeutics presently has a consensus price target of $3.83, suggesting a potential upside of 258.26%. Zevra Therapeutics has a consensus price target of $23.71, suggesting a potential upside of 113.45%. Given Fate Therapeutics' higher possible upside, research analysts plainly believe Fate Therapeutics is more favorable than Zevra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media refer more to FATE or ZVRA? In the previous week, Zevra Therapeutics had 11 more articles in the media than Fate Therapeutics. MarketBeat recorded 12 mentions for Zevra Therapeutics and 1 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 1.83 beat Zevra Therapeutics' score of 0.92 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zevra Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, FATE or ZVRA? Fate Therapeutics has a beta of 2.24, meaning that its share price is 124% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Do insiders and institutionals hold more shares of FATE or ZVRA? 97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 5.5% of Fate Therapeutics shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is FATE or ZVRA more profitable? Zevra Therapeutics has a net margin of -226.78% compared to Fate Therapeutics' net margin of -1,318.93%. Fate Therapeutics' return on equity of -47.17% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-1,318.93% -47.17% -34.60% Zevra Therapeutics -226.78%-201.05%-53.55% Which has higher earnings & valuation, FATE or ZVRA? Zevra Therapeutics has higher revenue and earnings than Fate Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M9.00-$186.26M-$1.49-0.72Zevra Therapeutics$23.61M25.73-$105.51M-$1.90-5.85 SummaryFate Therapeutics beats Zevra Therapeutics on 9 of the 17 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$126.06M$3.00B$5.47B$9.52BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-0.7217.6228.6723.80Price / Sales9.00270.05399.8778.09Price / CashN/A41.9535.4557.96Price / Book0.388.508.275.55Net Income-$186.26M-$55.06M$3.24B$259.03M7 Day Performance-13.71%-3.98%-3.64%-4.56%1 Month Performance-4.46%9.59%4.39%4.49%1 Year Performance-76.89%6.72%25.96%18.05% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics3.9677 of 5 stars$1.07-2.7%$3.83+258.3%-78.1%$126.06M$13.63M-0.72550Positive NewsAnalyst UpgradeZVRAZevra Therapeutics2.0705 of 5 stars$10.81-3.7%$23.71+119.4%+76.3%$591.09M$23.61M-5.6920Trending NewsShort Interest ↑Analyst RevisionTYRATyra Biosciences1.6466 of 5 stars$11.11+0.5%$30.83+177.5%-51.8%$589.83MN/A-6.8220News CoverageUpcoming EarningsShort Interest ↑KROSKeros Therapeutics2.5375 of 5 stars$14.51+0.3%$30.56+110.6%-71.6%$589.40M$3.55M-80.61100News CoverageUpcoming EarningsTRMLTourmaline Bio1.5599 of 5 stars$22.61+14.4%$49.33+118.2%+33.2%$580.63MN/A-7.0444Upcoming EarningsTSHATaysha Gene Therapies2.4297 of 5 stars$2.67+0.8%$8.17+205.9%+21.8%$573.14M$8.33M-7.85180News CoverageShort Interest ↑ARVNArvinas3.4676 of 5 stars$7.61-2.9%$20.29+166.6%-72.3%$555.46M$426.90M-11.53420News CoverageRZLTRezolute2.3449 of 5 stars$6.38+1.3%$11.83+85.5%+33.1%$555.06MN/A-5.5540TBPHTheravance Biopharma1.7973 of 5 stars$11.06+0.3%$16.60+50.1%+8.7%$553.01M$65.27M-9.37110Upcoming EarningsPRMEPrime Medicine3.7426 of 5 stars$4.09-2.9%$9.25+126.2%-22.2%$550.09M$3.85M-2.00234News CoverageInsider TradeGap DownSAGESage Therapeutics3.738 of 5 stars$8.78-0.2%$8.02-8.7%-11.0%$549.81M$47.40M-1.51690News CoveragePositive NewsEarnings ReportAnalyst UpgradeHigh Trading Volume Related Companies and Tools Related Companies Zevra Therapeutics Alternatives Tyra Biosciences Alternatives Keros Therapeutics Alternatives Tourmaline Bio Alternatives Taysha Gene Therapies Alternatives Arvinas Alternatives Rezolute Alternatives Theravance Biopharma Alternatives Prime Medicine Alternatives Sage Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FATE Stock Alerts